FGFR2 and neoplasm: Such successes are exemplified by BTC-specific approvals of fibroblast growth factor receptor (FGFR) inhibitors for tumours with <i>FGFR2</i> rearrangements, as well as mutant isocitrate dehydrogenase 1 inhibitors.